Otros idiomas Hansa Biopharma AB OTC Markets

Acciones

HNSBF

SE0002148817

Mercado cerrado - OTC Markets Otros sitios de cotización 14:30:14 14/03/2024			Varia. Cinco días.	Varia. 1 de enero.
2,93 ^USD	-9,98 %		-.--%	+29,82 %

31/05	Hansa Biopharma finaliza la aleatorización de pacientes para el uso de imlifidasa en un ensayo de trasplante renal	MT
31/05	Hansa Biopharma completa la aleatorización en el ensayo pivotal de fase 3 Us Confides	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial	31/05
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial	31/05
Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting	21/05
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04
Hansa Biopharma Hires New CFO	22/02
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	06/01
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	14/12
Hansa Biopharma Nomination Committee Formed	13/12
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	07/12
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	05/12
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables	05/12
Sweden's Hansa Biopharma CFO to Depart in February 2024	27/11
Transcript : Hansa Biopharma AB, Nine Months 2023 Earnings Call, Oct 26, 2023	26/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Hansa Biopharma AB OTC Markets

Acciones

HNSBF

SE0002148817

Otros idiomas

Filtros